Inhibitory effect of F-1322 on allergic eosinophil infiltration in airways.
The effects of F-1322 (N-[2-[4-(benzhydryloxy)piperidino]ethyl]-3-hydroxy-5-(3-pyridy lmethoxy)-2-naphthamide) on antigen-induced eosinophil infiltration and interleukin-5 production in the airways and on in vitro eosinophil migration were investigated. F-1322 (10-30 mg/kg, p.o.) inhibited antigen-induced eosinophil infiltration and interleukin-5 production in the airways of sensitized mice in a dose-dependent manner. Furthermore, F-1322 (0.1-10 microM) prevented the in vitro migration of eosinophils from guinea-pigs and humans induced by recombinant human interleukin-5, platelet-activating factor, and leukotriene B4 in a concentration-dependent manner. These results indicate that F-1322 has an inhibitory effect on allergic eosinophil infiltration of the airways by preventing both eosinophil migration and interleukin-5 production. These pharmacological profiles suggest that F-1322 will be a useful therapeutic for allergic diseases, especially asthma.
Mochizuki
A
A
Pharmaceuticals Research Laboratories, Fujirebio Inc., Hachioji, Tokyo, Japan.
Lee
B
B
Shibata
M
M
Kasai
M
M
Tanaka
T
T
Iwamoto
I
I
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid; D002465:Cell Movement / Q000187:drug effects*; D004804:Eosinophils / Q000166:cytology / Q000187:drug effects*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006967:Hypersensitivity / Q000473:pathology*; D015848:Interleukin-5 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009281:Naphthalenes / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects* / Q000473:pathology
D018927:Anti-Asthmatic Agents; C096516:F 1322; D015848:Interleukin-5; D009281:Naphthalenes